Anne E. Tebo, PhD

Research Interests

  • Autoimmune Diseases
  • Assay evaluation, development and standardization
  • Antiphospholipid Syndrome

Languages

  • English

Academic Information

  • Departments: Pathology - Professor (Clinical)
  • Divisions: Clinical Pathology

Board Certification

  • American Board of Medical Laboratory Immunology

Academic Office Information

  • 801-583-2787-Ext.3138
  • ARUP
    500 Chipeta Way
    Salt Lake City, UT 84108

Email: Anne.Tebo@aruplab.com

Academic Bio

Dr. Tebo is Professor of Pathology at the University of Utah School of Medicine and Medical Director of the Immunology Laboratory at ARUP Laboratories. She received her doctorate degree from the Eberhard Karls Universität Tübingen in Germany and completed postdoctoral training in immunology from the Department of Microbiology at the University of Birmingham at Alabama. Dr. Tebo continued her training with a clinical immunology fellowship at the Department of Pathology in the University of Utah School of Medicine. She is board certified in medical laboratory immunology by the American Board of Medical Laboratory Immunology (ABMLI) through the American College of Microbiology. Dr. Tebo is also a member of several professional societies, including the Association of Medical Laboratory Immunologists (AMLI), American Society of Microbiology (ASM), American Association of Clinical Chemists (AACC), and the American College of Rheumatology (ACR).

Research Statement

My research is primarily focused on understanding the role of antiphospholipid (aPL) antibodies in the evaluation and pathogenesis of antiphospholipid syndrome (APS). Other interests include evaluation, development and standardization of assays for the diagnosis and management of autoimmune diseases.

Education History

Type School Degree
Fellowship University of Utah
Clinical Immunology
Fellow
Postdoctoral Training University of Alabama at Birmingham
Microbiology (Viral Immunology)
Postdoctoral Training
Doctoral Training Eberhard Karls Universitat
Zoology (Malaria Immunology)
Ph.D.
Graduate Training University of Ibadan
Graduate Training University of Ibadan
Zoology (Malaria Immunology)
M.S.
Undergraduate Obafemi Awolowo University
Microbiology
B.S.
Undergraduate University of Calabar
Biological Sciences

Global Impact

Education History

Type School Degree Country
Doctoral Training Eberhard Karls Universitat
Zoology (Malaria Immunology)
Ph.D. Germany
Graduate Training University of Ibadan
Nigeria
Graduate Training University of Ibadan
Zoology (Malaria Immunology)
M.S. Nigeria
Undergraduate Obafemi Awolowo University
Microbiology
B.S. Nigeria
Undergraduate University of Calabar
Biological Sciences
Nigeria

Service

Date Role Description Country
06/06/2019 Active Member Global Lab Quality Initiative Africa Working Group Africa

Selected Publications

Journal Article

  1. Peterson LK, Tebo AE, Wener MH, Copple SS, Fritzler MJ (2020). Assessment of antinuclear antibodies by indirect immunofluorescence assay: report from a survey by the American Association of Medical Laboratory Immunologists. (Epub ahead of print) Clin Chem Lab Med.
  2. Tebo AE (2019). Laboratory Evaluation of Antiphospholipid Syndrome: An Update on Autoantibody Testing. Clin Lab Med, 39(4), 553-565.
  3. Heikal N, Martins TB, White SK, Willis R, Ware Branch D, Schmidt RL, Tebo AE (2019). Laboratory Evaluation of Antiphospholipid Syndrome. Am J Clin Pathol, 152(5), 638-646.
  4. Ravkov EV, Charlton CM, Barker AP, Hill H, Peterson LK, Slev P, Tebo A, Voelkerding KV, Wittwer CT, Heikal N, Delgado JC, Lzr-Molnr E, Kumnovics A (2019). Evaluation of Mass Cytometry in the Clinical Laboratory. Cytometry B Clin Cytom, 96(4), 266-274.
  5. Martins TB, Heikal N, Miller J, Willis R, Schmidt RL, Tebo AE (2018). Assessment of diagnostic methods for the detection of anticardiolipin and anti-βeta2 glycoprotein I antibodies in patients under routine evaluation for antiphospholipid syndrome. Clin Chim Acta, 485, 7-13.
  6. Gibbins KJ, Tebo AE, Nielsen SK, Branch DW (2018). Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study. Lupus, 27(12), 1903-1910.
  7. Peterson LK, Jaskowski TD, Laulu SL, Tebo AE (2018). Antibodies to small ubiquitin-like modifier activating enzyme are associated with a diagnosis of dermatomyositis: results from an unselected cohort. Immunol Res, 66(3), 431-436.
  8. Castanon A, Pierre G, Willis R, Harris EN, Papalardo E, Romay-Penabad Z, Schleh A, Jajoria P, Smikle M, DeCeulaer K, Tebo A, Jaskowski T, Guerra MM, Branch DW, Salmon JE, Petri M, Gonzalez EB (2018). Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin. Am J Clin Pathol, 149(5), 401-411.
  9. Tebo AE (2017). Recent Approaches To Optimize Laboratory Assessment of Antinuclear Antibodies. Clin Vaccine Immunol, 24(12).
  10. Jaskowski TD, Laulu SL, Mahler M, Tebo AE (2017). Detection of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme a reductase by ELISA in a reference laboratory setting. Clin Chim Acta, 472, 30-34.
  11. Sweeney M, Galli J, McNally S, Tebo A, Haven T, Thulin P, Clardy SL (2017). Delayed LGI1 seropositivity in voltage-gated potassium channel (VGKC)-complex antibody limbic encephalitis. BMJ Case Rep, 2017.
  12. Chiaro TR, Soto R, Zac Stephens W, Kubinak JL, Petersen C, Gogokhia L, Bell R, Delgado JC, Cox J, Voth W, Brown J, Stillman DJ, OConnell RM, Tebo AE, Round JL (2017). A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. Sci Transl Med, 9(380).
  13. Laulu SL, Suh-Lailam BB, Davis KW, Straseski JA, Tebo AE (2016). Comparative analysis of neutrophil gelatinase-associated lipocalin and other laboratory markers for lupus nephritis: a cross-sectional investigation. Ann Clin Biochem, 54(2), 240-245.
  14. Amengual O, Forastiero R, Sugiura-Ogasawara M, Otomo K, Oku K, Favas C, Delgado Alves J, igon P, Ambroi A, Tomi M, Ruiz-Arruza I, Ruiz-Irastorza G, Bertolaccini ML, Norman GL, Shums Z, Arai J, Murashima A, Tebo AE, Gerosa M, Meroni PL, Rodriguez-Pint I, Cervera R, Swadzba J, Musial J, Atsumi T (2016). Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus, 26(3), 266-276.
  15. Nandiwada SL, Peterson LK, Mayes MD, Jaskowski TD, Malmberg E, Assassi S, Satoh M, Tebo AE (2016). Ethnic Differences in Autoantibody Diversity and Hierarchy: More Clues from a US Cohort of Patients with Systemic Sclerosis. J Rheumatol, 43(10), 1816-1824.
  16. Tebo AE, Willis R, Jaskowski TD, Guerra M, Pierangeli SS, Salmon J, Petri M, Branch DW (2016). Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus. Clin Chim Acta, 460, 107-13.
  17. Tebo AE, Haven TR, Jackson BR (2016). Autoantibody diversity in paraneoplastic syndromes and related disorders: The need for a more guided screening approach. Clin Chim Acta, 459, 162-169.
  18. Willis R, Pierangeli SS, Jaskowski TD, Malmberg E, Guerra M, Salmon JE, Petri M, Branch DW, Tebo AE (2016). Performance Characteristics of Commercial Immunoassays for the Detection of IgG and IgM Antibodies to β2 Glycoprotein I and an Initial Assessment of Newly Developed Reference Materials for Assay Calibration. Am J Clin Pathol, 145(6), 796-805.
  19. Peterson LK, Jaskowski TD, Mayes MD, Tebo AE (2015). Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis. Immunol Res, 64(2), 483-8.
  20. Suh-Lailam BB, Davis KW, Tebo AE (2016). Immunoassays for the detection of IgA antibodies to tissue transglutaminase: significance of multiples of the upper limit of normal and inter-assay correlations. Clin Chem Lab Med, 54(2), 257-64.
  21. Peterson LK, Willis R, Harris EN, Branch WD, Tebo AE (2016). Antibodies to Phosphatidylserine/Prothrombin Complex in Antiphospholipid Syndrome: Analytical and Clinical Perspectives. Adv Clin Chem, 73, 1-28.
  22. Tebo AE (2015). Commentary. Clin Chem, 61(9), 1136-7.
  23. Heikal NM, Jaskowski TD, Malmberg E, Lakos G, Branch DW, Tebo AE (2015). Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort. Clin Exp Immunol, 180(2), 218-26.
  24. Tebo AE (2014). Antiphospholipid syndrome and the relevance of antibodies to negatively charged phospholipids in diagnostic evaluation. Lupus, 23(12), 1313-6.
  25. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, de Groot P, Lakos G, Lambert M, Meroni P, Ortel TL, Petri M, Rahman A, Roubey R, Sciascia S, Snyder M, Tebo AE, Tincani A, Willis R (2014). 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev, 13(9), 917-30.
  26. Suh-Lailam BB, Haven TR, Copple SS, Knapp D, Jaskowski TD, Tebo AE (2013). Anti-NMDA-receptor antibody encephalitis: performance evaluation and laboratory experience with the anti-NMDA-receptor IgG assay. Clin Chim Acta, 421, 1-6.
  27. Nandiwada SL, Tebo AE (2013). Testing for antireticulin antibodies in patients with celiac disease is obsolete: a review of recommendations for serologic screening and the literature. Clin Vaccine Immunol, 20(4), 447-51.
  28. Tebo AE, Jaskowski T, Davis KW, Whiting A, Clifford B, Zeft A, McNally B, Hill HR, Bohnsack J, Prahalad S (2012). Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J, 10(1), 29.
  29. Suh-Lailam BB, Cromar A, Davis KW, Tebo AE (2012). APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome. Int J Clin Exp Pathol, 5(3), 210-5.
  30. Jaskowski TD, Wilson AR, Hill HR, Tebo AE (2011). Diagnostic Assays for Anti-PM/Scl IgG Antibodies: Heterogeneity in Antibody Response or Lack of Standardization? Clin Chim Acta, 412(11-12), 1100-1105.
  31. Jaskowski TD, Wilson A, Hill HR, Tebo AE (2011). Diagnostic assays for anti-PM/Scl IgG antibodies: heterogeneity in antibody response or lack of standardization? Clin Chim Acta, 412(11-12), 1100-5.
  32. Chiaro TR, Davis KW, Wilson A, Suh-Lailam B, Tebo AE (2011). Significant differences in the analytic concordance between anti-dsDNA IgG antibody assays for the diagnosis of systemic lupus erythematosus--implications for inter-laboratory testing. Clin Chim Acta, 412(11-12), 1076-80.
  33. Suh-Lailam BB, Chiaro TR, Davis K W, Wilson AR, Tebo AE (2011). Evaluation of a high avidity anti-dsDNA IgG enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Int J Clin Exp Pathol, 4(8), 748-54.
  34. Hill HR, Augustine NH, Pryor RJ, Reed GH, Bagnato JD, Tebo AE, Bender JM, Pasi BM, Chinen J, Hanson IC, de Boer M, Roos D, Wittwer CT (2010). Rapid genetic analysis of x-linked chronic granulomatous disease by high-resolution melting. J Mol Diagn, 12(3), 368-76.
  35. Wyness SP, Laulu SL, Hunsaker JJ, Tebo AE, Roberts WL (2010). Performance characteristics of three random access cyclic citrullinated peptide antibody assays. Clin Chim Acta, 411(5-6), 428-432.
  36. Jaskowski TD, Wilson AR, Hill HR, Branch WD, Tebo AE (2009). Autoantibodies against phosphatidylserine, prothrombin and phosphatidylserine-prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome? Clin Chim Acta, 410(1-2), 19-24.
  37. Bender JM, Rand TH, Ampofo K, Pavia AT, Schober M, Tebo A, Pasi B, Augustine NH, Pryor RJ, Wittwer CT, Hill HR (2009). Family clusters of variant X-linked chronic granulomatous disease. Pediatr Infect Dis J, 28(6), 529-33.
  38. Martins TB, Jaskowski TD, Tebo A, Hill HR (2009). Development of a multiplexed fluorescent immunoassay for the quantitation of antibody responses to four Neisseria meningitidis serogroups. J Immunol Methods, 342(1-2), 98-105.
  39. Tebo AE, Jaskowski TD, Hill HR, Branch DW (2008). Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss. Clin Exp Immunol, 154(3), 332-8.
  40. Tebo AE, Jaskowski TD, Phansalkar AR, Litwin CM, Branch DW, Hill HR (2008). Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol, 129(6), 870-5.
  41. Prahalad S, Martins TB, Tebo AE, Whiting A, Clifford B, Zeft AS, McNally B, Bohnsack JF, Hill HR (2008). Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J, 6, 8.
  42. Tebo AE, Jaskowski TD, Keith LL, Litwin CM, Hill HR (2007). Comparison of immune assays for the detection of anti-HSP70 antibodies in patients with idiopathic sensorineural hearing loss. Clin Chim Acta, 381(2), 140-4.
  43. Tebo AE, Szankasi P, Hillman TA, Litwin CM, Hill HR (2006). Antibody reactivity to heat shock protein 70 and inner ear-specific proteins in patients with idiopathic sensorineural hearing loss. Clin Exp Immunol, 146(3), 427-32.
  44. Tebo AE, Fuller MJ, Gaddis DE, Kojima K, Rehani K, Zajac AJ (2005). Rapid recruitment of virus-specific CD8 T cells restructures immunodominance during protective secondary responses. J Virol, 79(20), 12703-13.
  45. Fuller MJ, Hildeman DA, Sabbaj S, Gaddis DE, Tebo AE, Shang L, Goepfert PA, Zajac AJ (2005). Cutting edge: emergence of CD127high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help. J Immunol, 174(10), 5926-30.
  46. Fuller MJ, Khanolkar A, Tebo AE, Zajac AJ (2004). Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. J Immunol, 172(7), 4204-14.
  47. Cabrera G, Yone C, Tebo AE, van Aaken J, Lell B, Kremsner PG, Luty AJ (2004). Immunoglobulin G isotype responses to variant surface antigens of Plasmodium falciparum in healthy Gabonese adults and children during and after successive malaria attacks. Infect Immun, 72(1), 284-94.
  48. Kohler C, Tebo AE, Dubois B, Deloron P, Kremsner PG, Luty AJ (2003). Temporal variations in immune responses to conserved regions of Plasmodium falciparum merozoite surface proteins related to the severity of a prior malaria episode in Gabonese children. Trans R Soc Trop Med Hyg, 97(4), 455-61.
  49. van der Kolk M, Tebo AE, Nimpaye H, Ndombol DN, Sauerwein RW, Eling WM (2003). Transmission of Plasmodium falciparum in urban Yaounde, Cameroon, is seasonal and age-dependent. Trans R Soc Trop Med Hyg, 97(4), 375-9.
  50. Tebo AE, Kremsner PG, Piper KP, Luty AJ (2002). Low antibody responses to variant surface antigens of Plasmodium falciparum are associated with severe malaria and increased susceptibility to malaria attacks in Gabonese children. Am J Trop Med Hyg, 67(6), 597-603.
  51. Tebo AE, Kremsner PG, Luty AJ (2002). Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. Clin Exp Immunol, 130(2), 300-6.

Review

  1. Lisa K Peterson, Anne E Tebo (2017). Autoantibody Testing in Myositis. [Review]. ASCP LabQ.
  2. Lazar-Molnar E, Tebo AE (2015). Autoimmune NMDA receptor encephalitis. [Review]. Clin Chim Acta, 438, 90-7.
  3. Tebo AE (2014). Biomarker diversity in lupus: challenges and opportunities. [Review]. Clinical Laboratory International, 38, 26-28.
  4. Tebo AE, Detrick B, Hamilton RG, Khanolkar A, OGorman MR, Schmitz JL, Abraham RS (2014). Clinical laboratory immunology: an indispensable player in laboratory medicine. [Review]. Am J Clin Pathol, 142(4), 437-44.
  5. Barakauskas, V, Tebo AE (2012). Testing for Celiac Disease. [Review]. ASCP LabQ.
  6. Tebo AE, Smock KJ, Branch WD (2011). Laboratory Diagnostic Assays for Antiphospholipid Syndrome. [Review]. ASCP CheckSample Series- Clinical Chemistry, 51(CC11-3), 33-47.
  7. Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, Kutteh WH, Lambert M, Matsubayashi H, Murthy V, Petri M, Rand JH, Sanmarco M, Tebo AE, Pierangeli SS (2011). 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. [Review]. Lupus, 20(2), 191-205.

Book Chapter

  1. Tebo AE (2010-present). Paraneoplastic Neurological Syndromes. In Jackson BR (Ed.), ARUP Consult: The physician's guide to laboratory test selection and interpretation. www.arupconsult.com.

Case Report

  1. Bender JM, Rand TH, Ampofo K, Pavia AT, Schober M, Tebo A, Pasi B, Augustine NH, Pryor RJ, Wittwer CT, Hill HR (2009). Family clusters of variant X-linked chronic granulomatous disease. Pediatr Infect Dis J, 28(6), 529-33.

Letter

  1. Tebo AE, Schmidt RL, Frech TM (2019). Dr. Tebo, et al, reply. [Letter to the editor]. J Rheumatol, 46(11), 1547.
  2. Tebo AE, Schmidt RL, Frech TM (2019). Presence of Antitopoisomerase I Antibody Alone May Not Be Sufficient for the Diagnosis of Systemic Sclerosis. [Letter to the editor]. J Rheumatol, 46(4), 440-442.
  3. Shirts B, von Roon AC, Tebo AE (2012). The entire predictive value of the prometheus IBD sgi diagnostic product may be due to the three least expensive and most available components. [Letter to the editor]. Am J Gastroenterol, 107(11), 1760-1.
  4. Haven TR, Astill ME, Pasi BM, Carper JB, Wu LL, Tebo AE, Hill HR (2010). An algorithm for acetylcholine receptor antibody testing in patients with suspected myasthenia gravis. [Letter to the editor]. Clin Chem, 56(6), 1028-9.

Abstract

  1. Amengual O, Forastiero R, Sugiura-Ogasawara M, Otomo K, Kenji O, Favas C, Delgado Alves J, igon P, Ambroi A, Tomi M, Ruiz Arruza I, Ruiz Irastorza G, Bertolaccini ML, Norman GL, Shums Z, Jiro A, Murashima A, Tebo AE, Gerosa M, Meroni PL, Rodriguez-Pint I, Cervera R, Swadzba J, Musial J, Atsumi T (2015). Significance of IGG Phosphatidylserine-Dependent Antiprothrombin Antibody Testing for the Diagnosis of Antiphospholipid Syndrome: Results from the Initial and Validation International Multi-Centre Studies [Abstract]. Annals of Rheumatic Diseases, 74 (Suppl 2)(155.2), 156.
  2. Py L, Tebo A, Godshall A (2011). Confirmation of Treatment Effectiveness for NMDA Receptor Encephalitis in Absence of Clinical Findings [Abstract]. Supplement to Critical Care Medicine, 39(12), 241.